Acute bronchospasm during passive exposure to bronchial provocation tests

To the Editor:

Bronchial challenge with direct stimuli, like histamine and methacholine, is very sensitive for diagnosing asthma and produces similar responses on a milligram-on-milligram or on a millimole-on-millimole basis [1–4]. American Thoracic Society (ATS)/European Respiratory Society (ERS) guidelines have proposed measures in order to protect technicians performing these tests, which include the use of good filters and ventilation, and have recommended that technicians with asthma should take extra precautions to minimise exposure or should avoid challenge testing. Performing methacholine/histamine challenge tests on technicians has also been thought to be useful [1]. Evidence however remains limited with only three published papers reporting some reaction to passive exposure in technicians [5–7], with two of these cited in the ATS/ERS guidelines [1]. One was a survey that only reported technicians’ symptoms during challenge tests [5], another described two nurses who developed increased airway responsiveness after 2 years of regular practice of histamine and methacholine challenge tests, and the third paper reported episodic bronchospasm in a female technician known to have stable and well-treated asthma [7].

We have prospectively investigated the risk of acute bronchospasm during passive exposure to histamine. We invited symptomatic patients with newly diagnosed high levels of bronchial hyperreactivity (PD20 (provocative concentration causing a 20% fall in forced expiratory volume in 1 s) at first histamine dose) to agree to be passively exposed to histamine within 7 days of their first test in a manner comparable to the technician’s passive exposure. We reasoned that if these patients showed no response to passive exposure, then the risk to asymptomatic technicians would be very small. The study was approved by the ethics committee (Saint-Pierre University Hospital, Brussels, Belgium) and participants filled in an informed consent form. For this exploratory and mainly descriptive study, a sample size of 12 patients was considered sufficient and the study was registered (NCT 01937494).

13 adult patients with symptoms (i.e. dyspnoea, non-productive cough, chest tightness and wheezing) not diagnostic for asthma, and positive histamine provocation test at first dose were included. None of them received asthma treatment. During the diagnostic test, the patient was seated in the body box cabin whose door remained open. The technician remained close to the cabin (about 1 m). In addition to the expiratory filter, a standard ventilation system was present in the room whose approximate surface area was 4 m². During the passive exposure test, the patients remained close to the technician, while the subjects actively exposed were now volunteers with previously known negative results.

The conventional 2-min tidal breathing histamine challenge test protocol was followed using Jaeger APS Pro (ERICH Jaeger GmbH, Wurzburg, Germany) and DeVilbiss 646 (Sunrise Medical HHG Inc., Somerset, PA, USA) jet nebuliser with an output of 900 μL·min⁻¹ and a distribution range of 2.1 μm [1, 3]. The expiratory filter was always changed after four challenge tests. We used a short protocol of five concentrations (0.9% saline as initial baseline control, histamine 1 and/or 2 mg·mL⁻¹, 4, 8, 16 and 32 mg·L⁻¹) with the 1 mg·mL⁻¹ concentration being usually given to patients with the highest suspicion of severe bronchial hyperreactivity [1, 8]. The forced expiratory volume in 1 s (FEV1) was obtained at each step about 30 and 90 s after nebulisation and the test was stopped if the FEV1 fall was equal to or exceeded 20% of baseline FEV1.

The corresponding dose for a 20% decrease in FEV1 (PD20) was then calculated and the results of active and passive exposure were compared.

13 patients (12 female) with normal FEV1 to forced vital capacity ratio (standardised residuals, z-scores, between −1.630 and 0.260) [9, 10] and no contraindication to histamine challenge test [1] were included. Symptoms at presentation included dyspnoea in 10 (77%), cough in eight (62%), chest tightness in two (15%) and wheezing in two (15%) patients. During active exposure to histamine, a positive reaction at the first dose was observed in all included patients with a PD20 <60 μg and a mean±SD FEV1 fall amounting to 830±270 mL. During passive exposure, no reaction was observed in 12 (92%) of the patients; one patient had a very mild reaction with a PD 20 at 614 μg (at a concentration of 16 mg·mL⁻¹ of histamine) (figure 1). None of the study patients felt chest tightness or showed cough during the passive exposure. No relationship appeared between the PD20 of the first diagnostic test and the passive PD20 or the last used dose without reaction of the passive test.
These data show that symptomatic subjects with reaction to lowest doses during histamine challenge test showed an absence of clinically significant response when they are exposed to histamine in conditions mimicking those of laboratory technicians performing the test. In contrast with previous studies that suggested a risk associated with passive exposure [5–7], mouthpiece and box valve on the expired side as well as adequate ventilation that minimised the exposure were used [2, 11]. The study from Lundgren et al. [6] also suggested that repeated passive exposure may lead to airway hyperreactivity. This is however in contradiction with previous findings in asthmatic patients showing that histamine provocation tests can be repeated without the appearance of tachyphylaxis or increased sensitivity to histamine [12].

Finally, the absence of response to passive exposure in symptomatic highly hyperreactive patients suggests that there is no need for a previous challenge testing in asymptomatic technicians starting to work in a lung function department.

No need for bronchial challenge testing in asymptomatic technicians commencing work in a lung function department http://ow.ly/S2D3z

Maria Gabrovska, Emmanuel Lacombe, Marie Bruyneel and Vincent Ninane
Chest Service, Saint-Pierre University Hospital, Brussels, Belgium.

Correspondence: Maria Gabrovska, Chest Service, Saint-Pierre University Hospital, Rue Haute 322, 1000 Brussels, Belgium. E-mail: maria_gabrovska@stpierre-bru.be

Received: Jan 10 2015 | Accepted after revision: July 24 2015

Conflict of interest: None declared.

Clinical trial: This study was registered with clinical trial number NCT 01937494.

References
10 Miller MR. Does the use of per cent of predicted have any evidence base? *Eur Respir J* 2015; 45: 322–323.
